Artificial intelligence (AI) methods have multiplied our capabilities to extract quantitative
information from digital histopathology images. AI is expected to reduce workload for human …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Background Standard first-line chemotherapy for endometrial cancer is paclitaxel plus
carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear …

Introduction Many advances in the understanding of the pathologic and molecular features
of endometrial cancer have occurred since the FIGO staging was last updated in 2009 …

Highlights•This ESMO Clinical Practice Guideline provides key recommendations for
managing endometrial cancer.•The guideline covers clinical and pathological diagnosis …

A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …

Endometrial cancer is the most common gynecological malignancy in high‐and middle‐
income countries. Although the overall prognosis is relatively good, high‐grade endometrial …

PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …